article
17 September 2019 | By Aino Palva (University of Helsinki), Lauri Paasonen (UPM Biomedicals), Pekka Ellonen (Helsinki Institute for Life Sciences), Piia Mikkonen (Institute for Molecular Medicine Finland), Vilja Pietiäinen (Institute for Molecular Medicine Finland)
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.